Impact of pregnancy on abacavir pharmacokinetics

Brookie M. Best, Mark Mirochnick, Edmund V. Capparelli, Alice Stek, Sandra K. Burchett, Diane T. Holland, Jennifer S. Read, Elizabeth Smith, Chengcheng Hu, Stephen A. Spector, James D. Connor

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Objective: To describe abacavir pharmacokinetics during pregnancy and postpartum; physiological changes during pregnancy are known to affect antiretroviral drug disposition. Design: The Pediatric AIDS Clinical Trials Group P1026s study is an on-going, prospective, non-blinded pharmacokinetic study of pregnant women receiving one or more antiretroviral drugs for routine clinical care, including a cohort receiving abacavir 300 mg twice daily. Methods: Serial plasma samples (predose, 1, 2, 4, and 6 h postdose) obtained antepartum (30-36 weeks of gestation) and again postpartum (6-12 weeks after delivery) were assayed for abacavir concentration by reversed-phase high-performance liquid chromatography. Results: Antepartum evaluations were available for 25 women [mean age, 28.6 years (SD, 6); mean third-trimester weight 92 kg (SD, 35.4); and race/ethnicity 52% black, 28% Hispanic, 16% white, 4% Asian], with geometric mean abacavir area under the concentration-time curve (AUC) of 5.9 mg·h/l [90% confidence interval (CI), 5.2-6.8] and maximum plasma concentration (Cmax) of 1.9 mg/l (90% CI, 1.6-2.2). Seventeen women completed postpartum sampling, and the ratios of antepartum to postpartum AUC and Cmax were 1.04 (90% CI, 0.91-1.18) and 0.79 (90% CI, 0.65-0.98), respectively. Conclusions: Abacavir AUC during pregnancy was similar to that at 6-12 weeks postpartum and to that for non-pregnant historical controls (5.8 mg·h/l). Consequently, pregnancy does not appear to affect overall abacavir exposure significantly or to necessitate dose adjustments.

Original languageEnglish (US)
Pages (from-to)553-560
Number of pages8
JournalAIDS
Volume20
Issue number4
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Keywords

  • AIDS
  • Antiretroviral agents
  • Drug monitoring
  • HIV
  • Pharmacokinetics
  • Pregnancy
  • Reverse transcriptase inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Impact of pregnancy on abacavir pharmacokinetics'. Together they form a unique fingerprint.

  • Cite this

    Best, B. M., Mirochnick, M., Capparelli, E. V., Stek, A., Burchett, S. K., Holland, D. T., Read, J. S., Smith, E., Hu, C., Spector, S. A., & Connor, J. D. (2006). Impact of pregnancy on abacavir pharmacokinetics. AIDS, 20(4), 553-560. https://doi.org/10.1097/01.aids.0000210609.52836.d1